The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition
Goodwin J, Neugent ML, Lee SY, Choe JH, Choi H, Jenkins DMR, Ruthenborg RJ, Robinson MW, Jeong JY, Wake M, Abe H, Takeda N, Endo H, Inoue M, Xuan Z, Yoo H, Chen M, Ahn JM, Minna JD, Helke KL, Singh PK, Shackelford DB, Kim JW. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nature Communications 2017, 8: 15503. PMID: 28548087, PMCID: PMC5458561, DOI: 10.1038/ncomms15503.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overAnimalsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell Line, TumorCohort StudiesDeoxyglucoseFemaleFluorodeoxyglucose F18Gene Expression ProfilingGene Expression Regulation, NeoplasticGlucoseGlucose Transporter Type 1GlycolysisHumansHydroxybenzoatesLungLung NeoplasmsMaleMiceMice, NudeMiddle AgedPhenotypePositron-Emission TomographyPrognosisSurvival AnalysisUp-RegulationXenograft Model Antitumor AssaysConceptsNon-small cell lung cancerSquamous cell carcinomaLung SqCCCell carcinomaNSCLC subtypesGlycolytic inhibitionLung squamous cell carcinomaCell lung cancerPatient-derived xenograftsNSCLC tumor samplesNSCLC cell linesCancer Genome AtlasClinical presentationPoor prognosisTherapeutic optionsLung cancerPredominant subtypeDistinct metabolic phenotypesSelective vulnerabilityLung adenocarcinomaMurine modelTherapeutic strategiesSqCCTumor samplesMetabolic signatures